Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis is under clinical development by CellTex Therapeutics and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis overview

Stem cell therapy is under development for the treatment of Alzheimer disease, rheumatoid arthritis and osteoarthritis. It is administered by intravenous and intraarticular route. The therapy comprises of autologous adipose-derived stem cells (AdMSCs).

CellTex Therapeutics overview

CellTex Therapeutics (CellTex) is an adult stem cell laboratory that provides stem cell banking and stem cell infusion services to their clients. It operates a bank to store adult stem cells for medical treatments. CellTex is headquartered in Houston, Texas, the US.

For a complete picture of Stem Cell Therapy for Alzheimer’s Disease, Osteoarthritis and Rheumatoid Arthritis’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.